ArticlemicroPublication biology2025
FHL2 fused with biotin ligase shuttles between focal adhesions and the nucleus in a myosin II-dependent manner.
Article in microPublication biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Four-and-a-half LIM domains 2 (FHL2) is a molecule that plays a key role in cell proliferation in response to mechanical signals. It shuttles between focal adhesions (FAs) or stress fibers (SFs) and the nucleus in a force-dependent manner. FHL2 interacts with other cytoskeletal molecules at FAs and SFs, but FHL2 interacts with transcriptional factors in the nucleus. This leads to modulation of gene expression for cell proliferation. However, the overall picture of interacting proteins with FHL2 at different regions is poorly understood. Here, we report a stable cell line that expresses FHL2-GFP-BirA, a fusion protein of FHL2 with biotin ligase. FHL2-GFP-BirA localizes at the FAs but accumulates in the nucleus after myosin II inhibition, exhibiting behavior similar to endogenous FHL2. These results suggest that the BioID technique can be used to identify proteins interacting with FHL2 under different mechanical conditions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.